Filter your search
Kalorama Information is a dependable resource for information on opportunity in the pharmaceutical market. The pharma industry has seen important developments in the last few years, bringing both challenges and new opportunities. The industry outlook for many manufacturers has changed due to outsourcing in drug discovery, growing generic competition and greater interest in biotechnology, among other developments. Our reports provide the sales data, revenue forecasts, and competitive analysis that one needs to understand the market.
Manufacturing & Packaging
- $2,812.00 – $5,625.00During the last 25 years, there have been unprecedented advancements in the area of women’s health and there is widespread recognition of the importance of addressing conditions that overwhelmingly affect women. Likewise, pharmaceutical marketers have increasingly understood the potential that the women’s health market represents and the increasing clout female consumers are wielding in the […]March 1, 2003$2,500.00 – $5,000.00Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the […]January 1, 2003$1,121.00 – $1,717.00In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resulting report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of […]January 1, 2003$995.00 – $5,990.00Since our last edition of this report in 2007, the oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the […]July 1, 2000